Efficacy of recombinant adeno-associated viral vectors serotypes 1, 2, and 5 for the transduction of pancreatic and colon carcinoma cells

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 1931-1935

  Teschendorf, Christian ^a   Emons, Barbara ^a   Muzyczka, Nicholas ^b   Graeven, Ullrich ^a   Schmiegel, Wolff ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer gene therapy; Recombinant AAV serotypes 1, 2, and 5; Solid tumor; Transduction efficiency

Indexed keywords

GREEN FLUORESCENT PROTEIN; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GENE THERAPY; CELL LINE; COLON CARCINOMA; EMBRYO; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION; KIDNEY CELL; MIXED INFECTION; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTYPE; TRANSGENE; VIRUS CAPSID; VIRUS RECOMBINANT; WILD TYPE;

CELL LINE; COLONIC NEOPLASMS; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HT29 CELLS; HUMANS; PANCREATIC NEOPLASMS; SEROTYPING; TRANSDUCTION, GENETIC;

EID: 77955066024     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Breyer B, Jiang W, Cheng H, Zhou L, Paul R, Feng T and He TC: Adenoviral vector-mediated gene transfer for human gene therapy. Curr Gene Ther 1: 149-162, 2001.
2. Ritter T, Lehmann M and Volk H: Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs 16: 3-10, 2002.
3. Warrington KH and Herzog RW: Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 119: 571-603, 2006.
4. Samulski RJ, Berns KI, Tan M and Muzyczka N: Cloning of adeno-associated virus into pBR322: Rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 79: 2077-2081, 1982.
5. High KA: Theodore E. Woodward award. AAV-mediated gene transfer for hemophilia. Trans Am Clin Climatol Assoc. 114: 337-351, 2003.
6. Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S, Brown BW, Desch JK, Norbash AM, Conrad CK, Guggino WB, Flotte TR, Wine JJ, Carter BJ, Reynolds TC, Moss RB and Gardner P: A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 13: 1349-1359, 2002.
7. Maass G, Bogedain C, Scheer U, Michl D, Horer M, Braun-Falco M, Volkenandt M, Schadendorf D, Wendtner CM, Winnacker EL, Kotin RM and Hallek M: Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. Hum Gene Ther 9: 1049-1059, 1998.
8. Veldwijk MR, Schiedlmeier B, Kleinschmidt JA, Zeller WJ and Fruehauf S: Superior gene transfer into solid tumour cells than into human mobilised peripheral blood progenitor cells using helpervirus-free adeno-associated viral vector stocks. Eur J Cancer 35: 1136-1142, 1999.
9. Teschendorf C, Warrington KH, Shi W, Siemann DW and Muzyczka N: Recombinant adeno-associated and adenoviral vectors for the transduction of pancreatic and colon carcinoma. Anticancer Res 26: 311-317, 2006.
10. Nguyen JT, Wu P, Clouse ME, Hlatky L and Terwilliger EF: Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res 58: 5673-5677, 1998.
11. Thorsen F, Afione S, Huszthy PC, Tysnes BB, Svendsen A, Bjerkvig R, Kotin RM, Lønning PE and Hoover F: Adeno- associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. J Gene Med 8: 1131-1140, 2006.
12. Choi VW, McCarty DM and Samulski RJ: AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther 5: 299-310, 2005.
13. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J and Wilson JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859, 2002.
14. Rabinowitz JE and Samulski RJ: Building a better vector: the manipulation of AAV virions. Virology 278: 301-308, 2000.
15. Grimm D and Kay MA: From virus evolution to vector revolution: use of naturally occurring serotypes of adeno- associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 3: 281-304, 2003.
16. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ and Walsh CE: Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2: 619-623, 2000.
17. Halbert CL, Allen JM and Miller AD: Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 75: 6615-6624, 2001.
18. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, Zabner J, Ghodsi A and Chiorini JA: Recombinant adeno- associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 97: 3428-3432, 2000.
19. Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ and Muzyczka N: Recombinant AAV viral pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10: 302-317, 2004.
20. Mingozzi F, Schuttrumpf J, Arruda VR, Liu Y, Liu YL, High KA, Xiao W and Herzog RW: Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol 76: 10497-10502, 2002.
21. Zolotukhin S, Potter M, Hauswirth WW, Guy J and Muzyczka N: A 'humanized' green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 70: 4646-4654, 1996.
22. Grimm D, Kern A, Rittner K and Kleinschmidt JA: Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 9: 2745-2760, 1998.
23. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ Jr, Chiodo VA, Phillipsberg T, Muzyczka N, Hauswirth WW, Flotte TR, Byrne BJ and Snyder RO: Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28: 158-167, 2002.
24. Zolotukhin S, Byrne B, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski R and Muzyczka N: Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973-985, 1999.
25. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T, Flotte T and Muzyczka N: Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 74: 8635-8647, 2000.
26. Teschendorf C, Warrington KH, Jr., Siemann DW and Muzyczka N: Comparison of the EF-1α and the CMV promoter for engineering stable tumor cell lines using recombinant adeno- associated virus. Anticancer Res 22: 3325-3330, 2002.
27. Daly T M, Okuyama T, Vogler C, Haskins ME, Muzyczka N and Sands MS: Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. Hum Gene Ther 10: 85-94, 1999.
28. Gorman CM, Gies D, McCray G and Huang M: The human cytomegalovirus major immediate early promoter can be transactivated by adenovirus early proteins: Virology 171: 377-385, 1989.
29. Kuppen PJ, van der Eb MM, Jonges LE, Hagenaars M, Hokland ME, Nannmark U, Goldfarb RH, Basse PH, Fleuren GJ, Hoeben RC and van de Velde CJ: Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer. Histochem Cell Biol 115: 67-72, 2001.
30. Gao G, Vandenberghe LH and Wilson JM: New recombinant serotypes of AAV vectors. Curr Gene Ther 5: 285-297, 2005.
31. Hacker UT, Wingenfeld L, Kofler DM, Schuhmann NK, Lutz S, Herold T, King SBS, Gerner FM, Perabo L, Rabinowitz J, McCarthy DM, Samulski RJ, Hallek M and Büning H: Adeno- associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. J Gene Med 7: 1429-1438, 2005.
32. Ferrari F, Samulski T, Shenk T and Samulski RJ: Second-strand synthesis is a rate limiting step for efficient transduction by recombinant adeno-associated viral vectors. J Virol 70: 3227-3234, 1996.
33. Warrington KJ jr, Teschendorf C, Cao L, Muzyczka N and Siemann DW: Virally directed enzyme/prodrug therapy using adeno-associated viral vectors: DT-diaphorase and bioreductive agents. Int J Rad Oncol Biol Phys 42: 909-912, 1998.
34. Vermeij J, Zeinoun Z, Neyns B, Teugels E, Bourgain C and De Gerve J: Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector. Br J Cancer 85: 1592-1599, 2001.
35. Peng D, Qian C, Sun Y, Barajas MA and Prieto J: Transduction of hepatocellular carcinoma (HCC) using recombinant adeno- associated virus (rAAV): in vitro and in vivo effects of genotoxic agents. J Hepatol 32: 975-985, 2000.
36. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P and Samulski RJ: Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10: 2112-2118, 2003.
37. Lee HS, Shin OK, Kim SJ, Lee WI, Jeong S, Park K, Choe H and Lee H: Efficient gene expression by self-complementary adeno-associated virus serotype 2 and 5 in various human cancer cells. Oncol Rep 18: 611-616, 2007.
38. Shi W, Teschendorf C, Muzyczka N and Siemann DW: Adeno- associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther 9: 513-521, 2002.
39. Davidoff AM, Nathwani AC, Spurbeck WW, Ng CY, Zhou J and Vanin, EF: rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice. Cancer Res 62: 3077-3083, 2002.